Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.66 |
| ▸ | MTOR | P42345 | 8/20 | 0.66 |
| ▸ | FLT3 | P36888 | 3/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769910 | 0.86 | PIK3CA (0.67) | PIK3CAMTORFLT3 | |
| SCHEMBL409076 | 0.80 | PIK3CA (1.00) | PIK3CAMTORPIK3CD | |
| SCHEMBL13180735 | 0.72 | FLT3 (1.00) | PIK3CAMTORFLT3MIF | |
| SCHEMBL770120 | 0.71 | PSEN1 (0.39) | PIK3CAMTORPIK3CD | |
| SCHEMBL380298 | 0.71 | PIK3CA (1.00) | PIK3CAMTORFLT3CDK1CDK4 | |
| SCHEMBL30655418 | 0.68 | FLT3 (0.69) | PIK3CAMTORFLT3MIF | |
| SCHEMBL29109646 | 0.68 | FLT3 (0.69) | PIK3CAMTORFLT3MIF | |
| SCHEMBL15756734 | 0.66 | FLT3 (0.61) | PIK3CAMTORFLT3MIFCDK1 | |
| SCHEMBL380433 | 0.66 | PIK3CA (1.00) | PIK3CAMTORPIK3CD | |
| SCHEMBL380333 | 0.65 | PIK3CA (1.00) | PIK3CAMTORPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729074-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729074-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120071474-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071474-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071474-A1 | INHIBITORS OF PI3 KINASE | PIK3CA, PIK3CD, PIK3CG | PIK3CA 1/4885MTOR 23/4885FLT3 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.